Elicitation of Potent Neutralizing Antibody Responses by Designed Protein Nanoparticle Vaccines for SARS-CoV-2
Cell.
2020-11;
Walls AC, Fiala B, Schäfer A, Wrenn S, Pham MN, Murphy M, Tse LV, Shehata L, O'Connor MA, Chen C, Navarro MJ, Miranda MC, Pettie D, Ravichandran R, Kraft JC, Ogohara C, Palser A, Chalk S, Lee EC, Guerriero K, Kepl E, Chow CM, Sydeman C, Hodge EA, Brown B, Fuller JT, Dinnon KH 3rd, Gralinski LE, Leist SR, Gully KL, Lewis TB, Guttman M, Chu HY, Lee KK, Fuller DH, Baric RS, Kellam P, Carter L, Pepper M, Sheahan TP, Veesler D, King NP
| Products/Services Used |
Details |
Operation |
| Gene Synthesis |
was synthesized by GenScript into pcDNA3.1- with an N-terminal mu-phosphatase signal peptide and a C-52420) was synthesized by GenScript into pCMV with an N-terminal mu-phosphatase signal peptide and a- and RBD-12GS-I53-50A fusions were synthesized and cloned by Genscript into pCMV. |
Get A Quote |
